SCHEMBL560905

SCHEMBL560905

CCOC(=O)c1cc(-c2ccccc2)c(C)n(-c2cccc(C(F)(F)F)c2)c1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.49
KDM4E B2RXH2 4/20 0.48
CYP1A2 P05177 2/20 0.48
CYP2C19 P33261 2/20 0.48
CYP2C9 P11712 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
ALDH1A1 P00352 3/20 0.48
HSD17B10 Q99714 2/20 0.48
CYP3A4 P08684 1/20 0.48
GAA P10253 1/20 0.48
LMNA P02545 1/20 0.46
GSR P00390 1/20 0.45
MAPT P10636 4/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
HTT P42858 1/20 0.44
APP P05067 1/20 0.44
ADORA1 P30542 1/20 0.44
ELANE P08246 1/20 0.44
TP53 P04637 1/20 0.44
HPGD P15428 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL560810 0.87 NOTUM (0.61) NOTUMCYP1A2NPSR1ALDH1A1LMNA
SCHEMBL31490345 0.85 NOTUM (0.53) NOTUMCYP1A2CYP2C9CYP3A4LMNA
SCHEMBL4157201 0.85 CYP1A2 (0.52) NOTUMKDM4ECYP1A2CYP2C19CYP2C9
SCHEMBL561882 0.84 CYP1A2 (0.51) NOTUMKDM4ECYP1A2CYP2C19CYP2C9
SCHEMBL7167969 0.82 LMNA (0.66) NOTUMCYP1A2CYP2C19CYP2C9NPSR1
SCHEMBL4021797 0.82 NOTUM (0.49) NOTUMKDM4ECYP1A2CYP2C19CYP2C9
SCHEMBL4157069 0.82 CYP1A2 (0.48) NOTUMKDM4ECYP1A2CYP2C19CYP2C9
SCHEMBL31490303 0.81 ELANE (0.48) NOTUMCYP1A2CYP2C19ALDH1A1CYP3A4
SCHEMBL560944 0.81 ELANE (0.48) NOTUMCYP1A2CYP2C19ALDH1A1CYP3A4
SCHEMBL560874 0.81 ELANE (0.57) NOTUMKDM4ECYP1A2CYP2C19CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1663973-B3 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE ASTRAZENECA AB (SE) 2019-09-25 EP disclosed
EP-1663973-B1 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE ASTRAZENECA AB (SE) 2013-12-25 EP disclosed
US-8501784-B2 2-pyridone derivatives as neutrophil elastase inhibitors and their use ASTRAZENECA AB (SE) 2013-08-06 US disclosed
US-20120035157-A1 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE ASTRAZENECA AB (SE) 2012-02-09 US disclosed
US-8063073-B2 2-pyridone derivatives as neutrophil elastase inhibitors and their use ASTRAZENECA AB (SE) 2011-11-22 US disclosed
US-20070203129-A1 2-Pyridone Derivatives As Neutrophil Elastase Inhibitors And Their Use ASTRAZENECA AB (SE) 2007-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035157-A1 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE SERPINB1, ELANE, SERPINE1 NOTUM 3528/4885KDM4E 3585/4885CYP1A2 330/4885
US-20070203129-A1 2-Pyridone Derivatives As Neutrophil Elastase Inhibitors And Their Use SERPINB1, ELANE, SERPINE1 NOTUM 3343/4885KDM4E 3424/4885CYP1A2 309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.